OSLO, Norway, June 14, 2017 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that updated results from its ongoing LYMRIT 37-01 Phase 1/2 clinical trial of Betalutin® (177Lu-satetraxetan-lilotomab) in patients with recurrent indolent non-Hodgkin's lymphoma (iNHL) are being...